Recent Finacing
Recent Raise
OrphoMed is a clinical-stage biopharmaceutical company developing dimer therapies; its proprietary ORP-101 is a metabolically stable, peripherally restricted μ partial agonist/κ antagonist targeting abdominal pain and hypermotility in IBS-D.
